The global Alzheimer's Therapeutics Market is projected to grow from USD 4.3 billion in 2026 to USD 10.4 billion by 2036, ...

The Cognitive Assessment & Training for Alzheimer's Disease Market was valued at USD 805.23 million in 2025 and is projected to reach USD 886.48 million in 2026, with a continuous ...

"I just know that my brain's not right," said Carrie Richardson, 44. "And so, I hate it. I just want it to be normal." At 41, Carrie developed early-onset Alzheimer's disease. The condition is caused ...

Alzheimer’s disease gradually worsens over time, and there’s no cure for it yet. Leqembi (lecanemab) is a new type of medicine that can slow down how quickly Alzheimer’s disease gets worse. Leqembi is ...

After a lull of nearly 2 decades, the Food and Drug Administration (FDA) has approved some novel drugs for the treatment of Alzheimer’s disease since 2021. Most of these drugs are antibody therapies ...